IP Verse

Angiopoietin-Like 3 (Angptl3) Irna Compostions And Methods Of Use Thereof

Patent No. EP2723758 (titled "Angiopoietin-Like 3 (Angptl3) Irna Compostions And Methods Of Use Thereof") was filed by Alnylam Pharmaceuticals on Jun 20, 2012. The application was issued on Jun 20, 2018.

Patent Summary

Double-stranded RNA (dsRNA) molecules for inhibiting expression of the ANGPTL3 gene, which is associated with disorders of lipid metabolism like hyperlipidemia and hypertriglyceridemia. The dsRNA has a short region of complementarity (15-30 nucleotides) to the mRNA of the ANGPTL3 gene. This region targets the mRNA for cleavage by RISC to inhibit translation and reduce ANGPTL3 protein levels. The short dsRNA length allows efficient uptake and RISC loading in cells.

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GRNECKERMar 19, 2019GRNECKER
GRUNECKER PATENT UND RECHTSANWALTE PARTG MBBMar 19, 2019GRUNECKER PATENT

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2723758

ALNYLAM PHARMACEUTICALS
Application Number
EP12802093A
Filing Date
Jun 20, 2012
Status
Revoked
Feb 2, 2024
Publication Date
Jun 20, 2018
External Links
Slate, Register , Google Patents